------ =_NextPart_000_01BCC9EF.A34F9640
Content-Type: text/plain; charset="us-ascii"
Content-Transfer-Encoding: 7bit
Is there a possibility that you send by e-mail this article, because in my country didn't arrive this magazine.
Thanks, I accept other way of you send. Very very thanks for your time
-----Mensaje original-----
De: Donna A. Bassolino [SMTP:[log in to unmask]]
Enviado el: Jueves 25 de Septiembre de 1997 16:28
Para: Multiple recipients of list PARKINSN
Asunto: article on PD drugs
There is a good article in the Journal
Trends in Pharmacology May 1997 Vol18 No5 pg 141
Parkinson's disease: prospects for impoved drug therapy
Authors: Haga/Middlemiss/Sharp & Post
It describes the classes of drugs including the new Pramipexol (mirapex)
and Roprinirole (ReQuip) ..as well as forthcoming COMT inhibitors etc.
Normally I would say this is a technical journal - but most of you
in this list know all the PD jargon and can handle this article easily.
donna
------------------------------------------------------------------------------
- Donna Bassolino-Klimas, Ph.D.
Bristol Myers Squibb Pharma. Res. Inst.
Department of Macromolecular Structure
P.O. Box 4000 Room H3812
Princeton, N.J. 08543 4000
(609) 252 4413
INTERNET: [log in to unmask]
------------------------------------------------------------------------------
------ =_NextPart_000_01BCC9EF.A34F9640
Content-Type: application/ms-tnef
Content-Transfer-Encoding: base64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------ =_NextPart_000_01BCC9EF.A34F9640--
